Yang Cui, Zhu Chunyan, Li Yanling, Li Zibiao, Zhang Zhenghao, Xu Jiajia, Chen Minwei, Li Runjing, Liu Shixiao, Wu Yunlong, Huang Zhengrong, Wu Caisheng
Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
Front Bioeng Biotechnol. 2022 Jul 11;10:912562. doi: 10.3389/fbioe.2022.912562. eCollection 2022.
Myocardial infarction (MI) is a serious threat to people's life and health, which is significantly hindered by effective treatment formulations. Interestingly, our recent endeavour of designing selenium-containing polymeric hydrogel has been experimentally proved to be helpful in combating inflammatory responses and treating MI. The design was inspired by selenium with anti-inflammatory and anti-fibrosis activities, and the formulation could also serve as a support of myocardial tissue upon the failure of this function. In details, an injectable selenium-containing polymeric hydrogel, namely, poly[di-(1-hydroxylyndecyl) selenide/polypropylene glycol/polyethylene glycol urethane] [poly(DH-SE/PEG/PPG urethane)], was synthesised by combining a thermosensitive PPG block, DH-Se (which has oxidation-reduction properties), and hydrophilic PEG segments. Based on the established mouse model of MI, this formulation was experimentally validated to effectively promote the recovery of cardiac function. At the same time, we confirmed by enzyme-linked immunosorbent assay, Masson staining and Western blotting that this formulation could inhibit inflammation and fibrosis, so as to significantly improve left ventricular remodelling. In summary, a selenium-containing polymeric hydrogel formulation analysed in the current study could be a promising therapeutic formulation, which can provide new strategies towards the effective treatment of myocardial infarction or even other inflammatory diseases.
心肌梗死（MI）对人们的生命和健康构成严重威胁，有效的治疗方案严重受限。有趣的是，我们最近设计含硒聚合物水凝胶的努力已通过实验证明有助于对抗炎症反应和治疗心肌梗死。该设计的灵感来源于具有抗炎和抗纤维化活性的硒，并且该制剂在心肌组织功能衰竭时还可作为心肌组织的支撑物。具体而言，通过将热敏性聚丙二醇（PPG）嵌段、具有氧化还原特性的二（1 - 羟基十二烷基）硒（DH - Se）和亲水性聚乙二醇（PEG）链段相结合，合成了一种可注射的含硒聚合物水凝胶，即聚[二（1 - 羟基十二烷基）硒/聚丙二醇/聚乙二醇聚氨酯] [聚（DH - SE/PEG/PPG聚氨酯）]。基于已建立的小鼠心肌梗死模型，通过实验验证该制剂能有效促进心脏功能的恢复。同时，我们通过酶联免疫吸附测定、Masson染色和蛋白质印迹法证实，该制剂可抑制炎症和纤维化，从而显著改善左心室重塑。总之，本研究中分析的含硒聚合物水凝胶制剂可能是一种有前景的治疗制剂，可为有效治疗心肌梗死甚至其他炎症性疾病提供新策略。
